This could be related to prevalence of the conditions treated by these therapies, with SMA estimated to be 3 to 4 times more prevalent than RPE65‐related inherited retinal dystrophy in the United States (U.S. and World Population Clock, 2023; Lloyd et al., 2019; Verhaart et al., 2017). The gene discussed is RPE65; the disease is inherited retinal dystrophy.